Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adrenergic antagonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Adrenergic antagonists. Displaying page 1 of 1.
    EudraCT Number: 2005-004060-24 Sponsor Protocol Number: Glaucoma Xalacam /Combigan Start Date*: 2005-11-24
    Sponsor Name:Department of Clinical Pharmacology
    Full Title: A double-masked randomized cross-over study comparing the effect of Xalacom (latanoprost/timolol) and Combigan (brimonidine/timolol) fixed combination on intraocular pressure and ocular blood flow ...
    Medical condition: Glaucoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005170-25 Sponsor Protocol Number: GNT-01-21 Start Date*: 2022-02-10
    Sponsor Name:Genetic S.p.A.
    Full Title: PHASE III MULTICENTER RANDOMIZED TRIAL OF PRESERVATIVE FREE LATANOPROST 50µG/ML VS XALATAN IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
    Medical condition: Patients with Open-Angle Glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084293 Unilateral glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006861-18 Sponsor Protocol Number: 20061212 Start Date*: 2007-03-26
    Sponsor Name:Department of Cardiology
    Full Title: Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation
    Medical condition: Aortic coarctation and late hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002069-52 Sponsor Protocol Number: 4045-301 Start Date*: 2017-01-23
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020172-30 Sponsor Protocol Number: 191622-100 Start Date*: 2010-08-16
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neur...
    Medical condition: Treatment of Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016800-22 Sponsor Protocol Number: I1A-MC-BPAE Start Date*: 2010-05-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022984-36 Sponsor Protocol Number: 201051 Start Date*: Information not available in EudraCT
    Sponsor Name:Santen Oy
    Full Title: A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to ...
    Medical condition: Patients diagnosed with ocular hypertension or open-angle glaucoma (primary open-angle glaucoma [POAG], capsular glaucoma or pigmentary glaucoma).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030043 Ocular hypertension LLT
    12.1 10036719 Primary open angle glaucoma LLT
    12.1 10035015 Pigmentary glaucoma LLT
    12.1 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) ES (Completed) PT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-004496-40 Sponsor Protocol Number: I5V-MC-TGAB Start Date*: 2013-03-01
    Sponsor Name:Eli Lilly and Company
    Full Title: Study of the Safety and Efficacy of LY3016859 after Multiple Intravenous Dosing in Diabetic Nephropathy Patients
    Medical condition: Chronic kidney disease associated with Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 100000004857 10012678 Diabetic nephropathy NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:51:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA